Invention Grant
- Patent Title: Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
-
Application No.: US17136428Application Date: 2020-12-29
-
Publication No.: US11648222B2Publication Date: 2023-05-16
- Inventor: Gabriel Ghiaur , Richard J. Jones , Salvador Alonso , Roshantha A. Chandraratna
- Applicant: Io Therapeutics, Inc. , The Johns Hopkins University
- Applicant Address: US TX Houston
- Assignee: IO Therapeutics, Inc.,The Johns Hopkins Univercity
- Current Assignee: IO Therapeutics, Inc.,The Johns Hopkins Univercity
- Current Assignee Address: US TX Spring; US MD Baltimore
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; Michelle Glasky Bergman
- The original application number of the division: US15777868
- Main IPC: A61K31/196
- IPC: A61K31/196 ; A61K45/06 ; A61K31/192 ; A61K31/4166 ; A61K31/454 ; A61K31/4196 ; A61K31/138 ; A61K31/58 ; A61K31/4545 ; A61K31/5685 ; A61K31/277 ; A61P35/00 ; A61K31/69
Abstract:
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Public/Granted literature
- US20210137866A1 USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER Public/Granted day:2021-05-13
Information query
IPC分类:
